Abstract
The prognosis of most patients with AML is poor due to frequent disease relapse. The cause of relapse is thought to be from the persistence of leukemia initiating cells (LIC’s) following treatment. Here we assessed RNA based changes in LICs from matched patient diagnosis and relapse samples using single-cell RNA sequencing. Previous studies on AML progression have focused on genetic changes at the DNA mutation level mostly in bulk AML cells and demonstrated the existence of DNA clonal evolution. Here we identified in LICs that the phenomenon of RNA clonal evolution occurs during AML progression. Despite the presence of vast transcriptional heterogeneity at the single cell level, pathway analysis identified common signaling networks involving metabolism, apoptosis and chemokine signaling that evolved during AML progression and become a signature of relapse samples. A subset of this gene signature was validated at the protein level in LICs by flow cytometry from an independent AML cohort and functional studies were performed to demonstrate co-targeting BCL2 and CXCR4 signaling may help overcome therapeutic challenges with AML heterogeneity. It is hoped this work will facilitate a greater understanding of AML relapse leading to improved prognostic biomarkers and therapeutic strategies to target LIC’s.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis
Clinical Epigenetics Open Access 11 July 2023
-
Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation
Nature Communications Open Access 31 May 2023
-
Integrating temporal single-cell gene expression modalities for trajectory inference and disease prediction
Genome Biology Open Access 05 September 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout








References
Estey EH. General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia. Semin Hematol. 2006;43:89–95.
Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer. 2005;5:311–21.
Hanekamp D, Cloos J, Schuurhuis GJ. Leukemic stem cells: identification and clinical application. Int J Hematol. 2017;105:549–57.
Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell. 2014;14:275–91.
Lechman ER, Gentner B, Ng SW, Schoof EM, van Galen P, Kennedy JA. et al. miR-126 regulates distinct self-renewal outcomes in normal and malignant hematopoietic stem cells. Cancer cell. 2016;29:214–28.
Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P. et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med. 2011;17:1086–93.
Jordan CT. The leukemic stem cell. Best Pr Res Clin Haematol. 2007;20:13–18.
Metzeler KH, Maharry K, Kohlschmidt J, Volinia S, Mrozek K, Becker H. et al. A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. Leukemia. 2013;27:2023–31.
Akinduro O, Weber TS, Ang H, Haltalli MLR, Ruivo N, Duarte D. et al. Proliferation dynamics of acute myeloid leukaemia and haematopoietic progenitors competing for bone marrow space. Nat Commun. 2018;9:519.
Hira VVV, Van Noorden CJF, Carraway HE, Maciejewski JP, Molenaar RJ. Novel therapeutic strategies to target leukemic cells that hijack compartmentalized continuous hematopoietic stem cell niches. Biochim Biophys Acta Rev Cancer. 2017;1868:183–98.
Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007;7:834–46.
Saito Y, Uchida N, Tanaka S, Suzuki N, Tomizawa-Murasawa M, Sone A. et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol. 2010;28:275–80.
Essers MA, Trumpp A. Targeting leukemic stem cells by breaking their dormancy. Mol Oncol. 2010;4:443–50.
Lee MC, Lopez-Diaz FJ, Khan SY, Tariq MA, Dayn Y, Vaske CJ. et al. Single-cell analyses of transcriptional heterogeneity during drug tolerance transition in cancer cells by RNA sequencing. Proc Natl Acad Sci U.S.A. 2014;111:E4726–35.
Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ. et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl J Med. 2013;368:2059–74.
Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND. et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl J Med. 2016;374:2209–21.
Bolouri H, Farrar JE, Triche T,Jr., Ries RE, Lim EL, Alonzo TA. et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24:103–12.
Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481:506–10.
Hughes AE, Magrini V, Demeter R, Miller CA, Fulton R, Fulton LL. et al. Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing. PLoS Genet. 2014;10:e1004462
Paguirigan AL, Smith J, Meshinchi S, Carroll M, Maley C, Radich JP. Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia. Sci Transl Med. 2015;7:281re282.
Li S, Garrett-Bakelman FE, Chung SS, Sanders MA, Hricik T, Rapaport F. et al. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nat Med. 2016;22:792–9.
Yan B, Hu Y, Ban KHK, Tiang Z, Ng C, Lee J. et al. Single-cell genomic profiling of acute myeloid leukemia for clinical use: a pilot study. Oncol Lett. 2017;13:1625–30.
Chen J, Kao YR, Sun D, Todorova TI, Reynolds D, Narayanagari SR. et al. Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level. Nat Med. 2019;25:103–10.
van Galen P, Hovestadt V, Wadsworth Ii MH, Hughes TK, Griffin GK, Battaglia S. et al. Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity. Cell. 2019;176:1265–81 e1224.
Wang ML, Bailey NG. Acute myeloid leukemia genetics: risk stratification and implications for therapy. Arch Pathol Lab Med. 2015;139:1215–23.
Baum CM, Weissman IL, Tsukamoto AS, Buckle AM, Peault B. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci U.S.A. 1992;89:2804–8.
Kersten B, Valkering M, Wouters R, van Amerongen R, Hanekamp D, Kwidama Z. et al. CD45RA, a specific marker for leukaemia stem cell sub-populations in acute myeloid leukaemia. Br J Haematol. 2016;173:219–35.
Majeti R, Park CY, Weissman IL. Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Cell Stem Cell. 2007;1:635–45.
Picelli S, Bjorklund AK, Faridani OR, Sagasser S, Winberg G, Sandberg R. Smart-seq2 for sensitive full-length transcriptome profiling in single cells. Nat Methods. 2013;10:1096–8.
Majeti R, Becker MW, Tian Q, Lee TL, Yan X, Liu R. et al. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc Natl Acad Sci U.S.A. 2009;106:3396–401.
Lin Y, Ghazanfar S, Strbenac D, Wang A, Patrick E, Lin DM, et al. Evaluating stably expressed genes in single cells. Gigascience. 2019;8:1–10.
Murga M, Jaco I, Fan Y, Soria R, Martinez-Pastor B, Cuadrado M. et al. Global chromatin compaction limits the strength of the DNA damage response. J Cell Biol. 2007;178:1101–8.
Liu S, Kharbanda S, Stone RM. OncoHist®, an rh histone 1.3 is cytotoxic acute myeloid leuk cells results altered downstr signal. Blood. 2014;124:3604–4.
Su C, Gao G, Schneider S, Helt C, Weiss C, O’Reilly MA. et al. DNA damage induces downregulation of histone gene expression through the G1 checkpoint pathway. EMBO J. 2004;23:1133–43.
Izquierdo-Bouldstridge A, Bustillos A, Bonet-Costa C, Aribau-Miralbes P, Garcia-Gomis D, Dabad M. et al. Histone H1 depletion triggers an interferon response in cancer cells via activation of heterochromatic repeats. Nucleic Acids Res. 2017;45:11622–42.
Torres CM, Biran A, Burney MJ, Patel H, Henser-Brownhill T, Cohen AS, et al. The linker histone H1.0 generates epigenetic and functional intratumor heterogeneity. Science. 2016;353:1–12.
Liebermann DA, Tront JS, Sha X, Mukherjee K, Mohamed-Hadley A, Hoffman B. Gadd45 stress sensors in malignancy and leukemia. Crit Rev Oncog. 2011;16:129–40.
Chamseddine AN, Cabrero M, Wei Y, Ganan-Gomez I, Colla S, Takahashi K. et al. PDE4 differential expression is a potential prognostic factor and therapeutic target in patients with myelodysplastic syndrome and chronic myelomonocytic leukemia. Clin Lymphoma, Myeloma Leuk. 2016;16:S67–73.
Smith PG, Wang F, Wilkinson KN, Savage KJ, Klein U, Neuberg DS. et al. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood. 2005;105:308–16.
Kim DU, Kwak B, Kim SW. Phosphodiesterase 4B is an effective therapeutic target in colorectal cancer. Biochem Biophys Res Commun. 2019;508:825–31.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
Scialdone A, Natarajan KN, Saraiva LR, Proserpio V, Teichmann SA, Stegle O. et al. Computational assignment of cell-cycle stage from single-cell transcriptome data. Methods. 2015;85:54–61.
Kreitz J, Schonfeld C, Seibert M, Stolp V, Alshamleh I, Oellerich T. et al. Metabolic plasticity of acute myeloid leukemia. Cells. 2019;8:8.
Decker T, Bogner C, Oelsner M, Peschel C, Ringshausen I. Antiapoptotic effect of interleukin-2 (IL-2) in B-CLL cells with low and high affinity IL-2 receptors. Ann Hematol. 2010;89:1125–32.
Lin MT, Juan CY, Chang KJ, Chen WJ, Kuo ML. IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of anti-apoptotic gene mcl-1. Carcinogenesis. 2001;22:1947–53.
Chen Y, Zhang F, Tsai Y, Yang X, Yang L, Duan S. et al. IL-6 signaling promotes DNA repair and prevents apoptosis in CD133+ stem-like cells of lung cancer after radiation. Radiat Oncol. 2015;10:227.
Ahmed NN, Grimes HL, Bellacosa A, Chan TO, Tsichlis PN. Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. Proc Natl Acad Sci U.S.A. 1997;94:3627–32.
Zeng GQ, Yi H, Li XH, Shi HY, Li C, Li MY. et al. Identification of the proteins related to p53-mediated radioresponse in nasopharyngeal carcinoma by proteomic analysis. J Proteom. 2011;74:2723–33.
Swa HL, Blackstock WP, Lim LH, Gunaratne J. Quantitative proteomics profiling of murine mammary gland cells unravels impact of annexin-1 on DNA damage response, cell adhesion, and migration. Mol Cell Proteom: MCP. 2012;11:381–93.
Lim LH, Pervaiz S. Annexin 1: the new face of an old molecule. FASEB J. 2007;21:968–75.
Guo C, Liu S, Sun MZ. Potential role of Anxa1 in cancer. Future Oncol. 2013;9:1773–93.
Zhu F, Wang Y, Zeng S, Fu X, Wang L, Cao J. Involvement of annexin A1 in multidrug resistance of K562/ADR cells identified by the proteomic study. OMICS. 2009;13:467–76.
Shukla V, Lu R. IRF4 and IRF8: governing the virtues of B Lymphocytes. Front Biol (Beijing). 2014;9:269–82.
Mattei F, Schiavoni G, Sestili P, Spadaro F, Fragale A, Sistigu A. et al. IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment. Neoplasia. 2012;14:1223–35.
Bi X, Hameed M, Mirani N, Pimenta EM, Anari J, Barnes BJ. Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis. Breast Cancer Res. 2011;13:R111.
Pogosova-Agadjanyan EL, Kopecky KJ, Ostronoff F, Appelbaum FR, Godwin J, Lee H, et al. The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemia. PloS ONE. 2013;8:e70812.
Zhao S, Wang J, Qin C. Blockade of CXCL12/CXCR4 signaling inhibits intrahepatic cholangiocarcinoma progression and metastasis via inactivation of canonical Wnt pathway. J Exp Clin Cancer Res. 2014;33:103.
Yu X, Shi W, Zhang Y, Wang X, Sun S, Song Z. et al. CXCL12/CXCR4 axis induced miR-125b promotes invasion and confers 5-fluorouracil resistance through enhancing autophagy in colorectal cancer. Sci Rep. 2017;7:42226.
Song ZY, Gao ZH, Chu JH, Han XZ, Qu XJ. Downregulation of the CXCR4/CXCL12 axis blocks the activation of the Wnt/beta-catenin pathway in human colon cancer cells. Biomed Pharmacother. 2015;71:46–52.
Lin XL, Xu Q, Tang L, Sun L, Han T, Wang LW, et al. Regorafenib inhibited gastric cancer cells growth and invasion via CXCR4 activated Wnt pathway. PLoS ONE. 2017;12:e0177335.
Hu TH, Yao Y, Yu S, Han LL, Wang WJ, Guo H. et al. SDF-1/CXCR4 promotes epithelial-mesenchymal transition and progression of colorectal cancer by activation of the Wnt/beta-catenin signaling pathway. Cancer Lett. 2014;354:417–26.
Lu Y, Hu B, Guan GF, Chen J, Wang CQ, Ma Q. et al. SDF-1/CXCR4 promotes F5M2 osteosarcoma cell migration by activating the Wnt/beta-catenin signaling pathway. Med Oncol. 2015;32:194
Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol. 2011;29:591–9.
Tabe Y, Konopleva M. Role of microenvironment in resistance to therapy in AML. Curr Hematol Malig Rep. 2015;10:96–103.
Cancilla D, Rettig MP, DiPersio JF. Targeting CXCR4 in AML and ALL. Front Oncol. 2020;10:1672.
Pollyea DA, Amaya M, Strati P, Konopleva MY. Venetoclax for AML: changing the treatment paradigm. Blood Adv. 2019;3:4326–35.
Gupta K, Stefan T, Ignatz-Hoover J, Moreton S, Parizher G, Saunthararajah Y. et al. GSK-3 inhibition sensitizes acute myeloid leukemia cells to 1,25D-mediated differentiation. Cancer Res. 2016;76:2743–53.
Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R. et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 2017;7:716–35.
Hattori A, Tsunoda M, Konuma T, Kobayashi M, Nagy T, Glushka J. et al. Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia. Nature. 2017;545:500–4.
Bonen A, Campbell SE, Benton CR, Chabowski A, Coort SL, Han XX. et al. Regulation of fatty acid transport by fatty acid translocase/CD36. Proc Nutr Soc. 2004;63:245–9.
Schweikhard ES, Ziegler CM. Amino acid secondary transporters: toward a common transport mechanism. Curr Top Membr. 2012;70:1–28.
Ye H, Adane B, Khan N, Sullivan T, Minhajuddin M, Gasparetto M. et al. Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche. Cell Stem Cell. 2016;19:23–37.
Jones CL, Stevens BM, D’Alessandro A, Reisz JA, Culp-Hill R, Nemkov T. et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell. 2018;34:724–40 e724.
Tsun ZY, Possemato R. Amino acid management in cancer. Semin Cell Dev Biol. 2015;43:22–32.
Jones CL, Stevens BM, D’Alessandro A, Culp-Hill R, Reisz JA, Pei S. et al. Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II. Blood. 2019;134:389–94.
Peled A, Klein S, Beider K, Burger JA, Abraham M. Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies. Cytokine. 2018;109:11–6.
Cho BS, Kim HJ, Konopleva M. Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside. Korean J Intern Med. 2017;32:248–57.
Carter BZ, Gronda M, Wang Z, Welsh K, Pinilla C, Andreeff M. et al. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood. 2005;105:4043–50.
Cassier PA, Castets M, Belhabri A, Vey N. Targeting apoptosis in acute myeloid leukaemia. Br J Cancer. 2017;117:1089–98.
Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. Clin Adv Hematol Oncol. 2014; 12: 18–19.
Brinda B, Khan I, Parkin B, Konig H. The rocky road to personalized medicine in acute myeloid leukaemia. J Cell Mol Med. 2018;22:1411–27.
DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M. et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19:216–28.
Kayser S, Levis MJ. Advances in targeted therapy for acute myeloid leukaemia. Br J Haematol. 2018;180:484–500.
Thomas D, Majeti R. Biology and relevance of human acute myeloid leukemia stem cells. Blood. 2017;129:1577–85.
Acknowledgements
The authors are grateful to the patients who contributed to this study and thank the Children’s Oncology Group for providing some of the bone marrow samples used in this study. This study was supported by pilot funding from the Case Comprehensive Cancer Center (NCI P30CA0437093) and the Computational Genomic Epidemiology of Cancer Fellowship (NCI 5T32CA094186-17, L.S.). This research was also supported by the following Shared Resources of the Case Comprehensive Cancer Center (NCI P30CA0437093): Hematopoietic Cell Biorepository and Cellular Therapy, Integrated Genomics, and Cytometry & Imaging Microscopy. This work made use of the High Performance Computing Resources in the Core Facility for Advanced Research Computing at Case Western Reserve University. The authors thank Jose Cancelas, Folashade Otegbeye, Sheela Karunaithi, and Grace Lee for their scientific feedback and Caroline Perry and Kristin Waite for their critical reading and editing of the paper.
Author information
Authors and Affiliations
Contributions
DW conceived of and supervised the project. DB, TS, and KG performed single cell RNA sequencing experiments. LS designed and performed the computational analysis. SF, AS, JB-S, TH, ZJ, RS, and SL contributed to the computational analysis. DW, RS, SPR, RB, AR, XX, and BT designed, optimized, implemented, analyzed and interpreted the flow cytometry data. JM, YS, and ML provided AML samples and assisted in data analysis and interpretation. DW and LS wrote the paper with contributions from RS, ZJ, TL, JB-S, YS, JM, AR, SPR, and DB.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Stetson, L.C., Balasubramanian, D., Ribeiro, S.P. et al. Single cell RNA sequencing of AML initiating cells reveals RNA-based evolution during disease progression. Leukemia 35, 2799–2812 (2021). https://doi.org/10.1038/s41375-021-01338-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-021-01338-7
This article is cited by
-
Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis
Clinical Epigenetics (2023)
-
Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation
Nature Communications (2023)
-
Integrated single-cell transcriptome analysis of CD34 + enriched leukemic stem cells revealed intra- and inter-patient transcriptional heterogeneity in pediatric acute myeloid leukemia
Annals of Hematology (2023)
-
Integrating temporal single-cell gene expression modalities for trajectory inference and disease prediction
Genome Biology (2022)
-
Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia
Molecular Cancer (2022)